Maplight Therapeutics (NASDAQ:MPLT) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Maplight Therapeutics (NASDAQ:MPLT) in a report issued on Monday, MarketBeat.com reports. The firm issued a buy rating and a $45.00 target price on the stock.

Several other analysts have also recently issued reports on MPLT. Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. TD Cowen assumed coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Wall Street Zen cut Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Needham & Company LLC assumed coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics Stock Performance

Shares of MPLT traded up $0.48 during trading hours on Monday, hitting $29.09. 36,359 shares of the stock were exchanged, compared to its average volume of 231,061. Maplight Therapeutics has a 12-month low of $12.24 and a 12-month high of $33.28. The firm has a market capitalization of $1.23 billion and a P/E ratio of -0.73. The stock has a 50-day moving average price of $22.19.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42). On average, equities analysts forecast that Maplight Therapeutics will post -3.87 earnings per share for the current year.

Insider Buying and Selling at Maplight Therapeutics

In other news, insider Anatol Kreitzer sold 45,422 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the completion of the transaction, the insider directly owned 211,190 shares in the company, valued at approximately $6,263,895.40. This represents a 17.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Pavlov purchased 10,658 shares of the stock in a transaction dated Wednesday, February 18th. The shares were acquired at an average price of $17.48 per share, with a total value of $186,301.84. Following the completion of the acquisition, the director owned 10,658 shares in the company, valued at approximately $186,301.84. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 39,124 shares of company stock worth $693,846 and sold 148,431 shares worth $4,040,428.

Hedge Funds Weigh In On Maplight Therapeutics

Several hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics during the 4th quarter worth about $49,168,000. Invesco Ltd. acquired a new position in Maplight Therapeutics during the 4th quarter worth about $228,000. Vestal Point Capital LP acquired a new position in Maplight Therapeutics during the 4th quarter worth about $6,763,000. Tudor Investment Corp ET AL acquired a new position in Maplight Therapeutics during the 4th quarter worth about $840,000. Finally, Orbimed Advisors LLC acquired a new position in Maplight Therapeutics during the 4th quarter worth about $952,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.